

RESEARCH ARTICLE

Open Access

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis

Georgios Iliadis^{1,2,8*}, Vassiliki Kotoula³, Athanasios Chatziosotiriou⁴, Despina Televantou³, Anastasia G Eleftheraki⁵, Sofia Lambaki⁶, Despina Misailidou¹, Panagiotis Selviaridis⁷ and George Fountzilias⁶

Abstract

Background: In this study several tumor-related volumes were assessed by means of a computer-based application and a survival analysis was conducted to evaluate the prognostic significance of pre- and postoperative volumetric data in patients harboring glioblastomas. In addition, MGMT (O⁶-methylguanine methyltransferase) related parameters were compared with those of volumetry in order to observe possible relevance of this molecule in tumor development.

Methods: We prospectively analyzed 65 patients suffering from glioblastoma (GBM) who underwent radiotherapy with concomitant adjuvant temozolomide. For the purpose of volumetry T1 and T2-weighted magnetic resonance (MR) sequences were used, acquired both pre- and postoperatively (pre-radiochemotherapy). The volumes measured on preoperative MR images were necrosis, enhancing tumor and edema (including the tumor) and on postoperative ones, net-enhancing tumor. Age, sex, performance status (PS) and type of operation were also included in the multivariate analysis. MGMT was assessed for promoter methylation with Multiplex Ligation-dependent Probe Amplification (MLPA), for RNA expression with real time PCR, and for protein expression with immunohistochemistry in a total of 44 cases with available histologic material.

Results: In the multivariate analysis a negative impact was shown for pre-radiochemotherapy net-enhancing tumor on the overall survival (OS) ($p = 0.023$) and for preoperative necrosis on progression-free survival (PFS) ($p = 0.030$). Furthermore, the multivariate analysis confirmed the importance of PS in PFS and OS of patients. MGMT promoter methylation was observed in 13/23 (43.5%) evaluable tumors; complete methylation was observed in 3/13 methylated tumors only. High rate of MGMT protein positivity (> 20% positive neoplastic nuclei) was inversely associated with pre-operative tumor necrosis ($p = 0.021$).

Conclusions: Our findings implicate that volumetric parameters may have a significant role in the prognosis of GBM patients. Furthermore, volumetry could help not only to improve the prediction of outcome but also the outcome itself by identifying patients at high risk of treatment failure and, thus, seek alternative treatment for these patients. In this small series, MGMT protein was associated with less aggressive tumor characteristics.

Background

Glioblastoma (GBM) is still one of the most uniformly fatal tumors. Although various radiotherapy techniques and altered fractionation schedules [1-6], as well as different chemotherapeutic regimens [7,8] have been implemented, the overall survival of glioblastoma patients remains rather poor, with a median survival of 12-18 months. A major problem concerning the study

of these patients is the identification of robust prognostic parameters. Evaluation of prognostic factors is vital to improve research pursuing new therapies for glioblastomas, since a better randomization or stratification into various treatment arms can be achieved.

In brain tumor research, the importance of tumor size as one of them has long been debated. In contrast to other tumor sites (head and neck, ovary, uterine cervix, stomach), there are numerous studies [9-15] marking out tumor size as a prognostic factor or as a predictor of outcome of certain therapies.

* Correspondence: iliadisgeo@gmail.com

¹Department of Radiation Oncology, "Papageorgiou" Hospital, Thessaloniki, Greece

Full list of author information is available at the end of the article

Treatment of high grade gliomas, glioblastomas included, involves radiotherapy with concomitant administration of the alkylating agent temozolomide [16]. The addition of temozolomide seems to benefit patients with tumors exhibiting methylated CpG islands at the promoter and enhancer regions of the gene encoding for O⁶-methylguanine methyltransferase (*MGMT*) [17,18]. The assessment of *MGMT* promoter methylation is currently considered as mandatory for patient selection in clinical trials [19]; testing for *MGMT* methylation is nevertheless still not officially requested as a marker predictive for temozolomide response in clinical practice, mainly due to methodological shortcomings [20] and to the lack of alternative treatment options in patients without *MGMT* promoter methylation [16]. In addition, the prognostic significance of *MGMT* promoter methylation regardless of therapeutic intervention remains controversial [17,21].

In the present study, we explored the prognostic significance of several volumetric parameters, for overall survival and progression-free survival in patients harboring glioblastoma and treated postoperatively with radiotherapy and temozolomide. Our purpose was to decide if there is still a role of the volumetric MR (magnetic resonance) data in prognostic categorization of glioblastoma patients. This could be of crucial importance in designing future studies with more intensive therapeutic schemes. In addition, we compared *MGMT* related parameters with those of volumetry in order to observe possible implications of this molecule in tumor development and, subsequently, treatment response.

Methods

Patients

In this single-institutional prospective study, 65 patients older than 18 years of age with newly diagnosed and histologically proven glioblastoma (World Health Organization [WHO] grade IV astrocytoma), who attended clinics from July 2005 to August 2007 of Radiation Oncology in Papanicolaou General Hospital of Thessaloniki, Greece or Medical Oncology of Aristotle University of Thessaloniki in the same hospital, were enrolled in the study. Other eligibility criteria included: a) preoperative MRI scan b) WHO performance status of 2 or less c) adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥ 1500 per cubic millimeter; platelet count, $\geq 100,000$ per cubic millimeter; serum creatinine level, ≤ 1.5 times the upper limit of normal in the laboratory where it was measured; total serum bilirubin level, ≤ 1.5 times the upper limit of normal; and liver-function values, < 3 times the upper limit of normal for the laboratory). The study was approved by the Ethics committee of Aristotle University of Thessaloniki, Greece and written informed consent was provided for every patient included.

Treatment

All patients received radiotherapy and chemotherapy with Temozolomide. Radiotherapy was delivered using linear accelerators with energy of 6 and/or 18 MV and consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over a period of six weeks, for a total dose of 60 Gy. All patients were treated supine and a thermoplastic mask was used as an immobilization device. For all patients we used CT simulation and the plan was performed with three-dimensional planning systems. Target volumes were based on postoperative MRIs. Two gross tumor volumes (GTV) were defined. The initial GTV (GTV1) was defined as T2 or FLAIR abnormality, including any enhancement in T1 and the surgical cavity, and the boost GTV (GTV2) as the contrast enhanced T1 abnormality, including the surgical cavity. The corresponding clinical target volumes (CTV1 and CTV2) and planning target volumes (PTV1 and PTV2) were generated by adding 2 cm on the GTVs to account for sub-diagnostic infiltration and 0.5 cm on the CTVs to account for variations in set-up and reproducibility, respectively. The initial target volume (PTV1) was treated to 44 Gy and afterwards the PTV2 for the rest 16 Gy, to a total of 60 Gy.

Chemotherapy with Temozolomide consisted of concurrent and adjuvant to radiation therapy phase in accordance with the EORTC 26981/22981; NCIC CE3 intergroup trial [22], with slight variations. After completion of 6 cycles of chemotherapy it was at the investigator's discretion to continue for 6 more cycles depending on response to the therapy.

MRI acquisition and volumetry

All patients underwent pre- and postoperative MRI (magnetic resonance imaging) scans. The postoperative MRI scan was acquired one week before the initiation of radiotherapy and at least 21 days after surgery, as we waited for the acute postoperative abnormalities to subside.

For the purpose of volumetry, T1 and T2-weighted MR sequences were used. Since the MR scans were not available in an electronic format, but only in hard copies, they were digitized, by means of a commercial high-resolution scanner. Before determining tumor volume with our specialized software, images were converted to the widely used DICOM (Digital Imaging and Communications in Medicine) format with a different computer application. Our volumetric method was previously described in detail [23]. Briefly, the investigator contoured the volume of interest (VOI) on each MR slice. The software was able to calculate the volume of the VOI using the following formula:

$$V = \sum S_i * z$$

Where V is the volume of the VOI, S_i the surface included by the contour of the VOI on each slice and z the slice thickness. The accuracy of this method is inversely proportional to slice thickness (Figure 1 and 2).

The volumes measured on preoperative MRIs were necrosis, enhancing tumor (including any region of central necrosis) and edema-T2 abnormality (including the tumor) and on postoperative ones-prior to radiochemotherapy (preRCT), net enhancing tumor. In the case of multifocal lesions, the sum of all measurable lesions was analyzed. All images were assessed by the same experienced radiation oncologist. Volumetry was performed before or during concurrent radiochemotherapy phase, as we tried to avoid bias from retrospective evaluation.

Response evaluation and follow-up

During concurrent radiochemotherapy patients were evaluated weekly, clinically and with full blood counts and blood chemistry tests. Twenty-one to 28 days after the

completion of the concurrent phase, patients underwent a comprehensive evaluation including radiologic assessment of the tumor with MRI. During adjuvant temozolomide therapy, patients underwent a monthly clinical evaluation and a comprehensive evaluation (including MRI) every 3 months until there was tumor progression or after two years of follow-up and every 3-4 months thereafter. The follow-up was updated on the May 4, 2010.

Tumor progression was defined according to MacDonald's response criteria [24]. When there was tumor progression patients were treated at their oncologist's discretion and the type of second-line therapy was recorded. Toxic effects were graded according to the National Cancer Institute Common Toxicity Criteria, version 3.0.

MGMT promoter methylation status, MGMT mRNA and protein expression

Among the patients included in this study, formalin-fixed paraffin embedded (FFPE) material from stereotactic




Figure 1 (a-g)-Example of contouring. Preoperative enhancing tumor in a glioblastoma patient.




Figure 2 Volumetry. Three-dimensional reconstruction of the volume, based on the regions of interest contoured in Figure 1. The number in the left bottom corner represents the tumor volume in cc.

biopsies and partial or complete resections of the tumors was available for analysis for 44 patients (tumor tissue bank of the Hellenic Cooperative Oncology Group). The above tumors were used for Tissue MicroArray (TMA) construction (2 × 1.5 mm cores per tumor) and for DNA and RNA extraction.

DNA and RNA extraction were accomplished on manually microdissected whole sections at a total depth of 40 μm for RNA and of 60 μm for DNA. DNA was extracted with the QIAamp mini kit (Qiagen, Hilden, Germany) and RNA with Trizol-LS (Invitrogen, Paisley, UK) according to standard procedures. For first strand cDNA synthesis the Superscript III system with random primers and a final RNase H RNA removing step were employed (all from Invitrogen). DNA samples were normalized at 100 ng/ul, cDNA samples at 50 ng/ul; all samples were stored at -20°C until use. DNA quality was assessed with the multiplex PCR DNA control assay from BIOMED2 and RNA quality was evaluated with real time PCR (QRT-PCR) by employing a Taqman-MGB assay for beta-glucuronidase (*GUSB*) as endogenous control (assay ID: 4333767 F [Applied Biosystems]).

MGMT promoter methylation was evaluated with the Multiplex Ligation-dependent Probe Amplification (MLPA[®]) and the SALSA MS-MLPA KIT ME011 testing for methylation at three distinct CpG sites in the

MGMT enhancer. The procedure and the evaluation of the results were accomplished according to the instructions of the manufacturer (MRC-Holland) and repeated twice to assess concordance of results (retention of the sample in the same category of methylation status). Evaluable results were yielded for 23/44 DNA tumor samples only (52.3%), all of which had amplification capacity for ≥ 300 bp, as revealed with the multiplex DNA control test.

MGMT gene expression was assessed by using a pre-made Taqman-MGB assay (Assay ID: Hs00172470_m1 [Applied Biosystems], ex 3-4, ref seq: NM_002412.3). Runs were performed for sample duplicates and readings were carried out at default settings in an ABI7500 real time PCR system equipped with the SDS v1.4 software. Upon initial control for cDNA amplification capacity, 41/44 samples yielded CT (cycle threshold) values ≤ 29 for the endogenous control amplicon (*GUSB*, as described above). Relative expression was assessed as the average 2^{-dCT} value (relative quantification value [RQ]) based on equal PCR efficiencies for very short amplicons [25] whereby dCT = *MGMT* CT - *GUSB* CT. Individual RQ values did not differ by more than 0.8 arbitrary units between duplicates.

Immunohistochemistry (IHC) for *MGMT* was performed on TMA sections of 2 μm, using the monoclonal

antibody MAB16200 (Chemicon, clone: MT3.1, anti-mouse), according to the instructions of the manufacturer (antigen retrieval: EDTA, dilution: 1:50). MGMT protein expression was evaluated with two different cut-offs, (a) 5% (absent \leq 5%; present: $>$ 5%) and (b) 20% (low \leq 20%; high: $>$ 20%) of tumor cells, respectively (modified after [17,26]).

Statistical analysis

Categorical data are presented as frequencies and corresponding percentages, while continuous data are presented as median and range. 95% exact confidence intervals using binomial distribution for treatment responses are also given. For all measured volumes, exploratory analysis was performed using the quartiles of the corresponding distribution as predefined cut-offs, testing their distinguishing ability in patient's prognosis. For each cut-off, tumors were categorized in two categories (small vs. large volume). MGMT mRNA expression was assessed as a continuous and MGMT promoter methylation and protein expression as categorical variables.

Overall survival (OS) was measured from time of operation to patient's last contact or death. Progression free survival (PFS) was measured from time of operation to patient's last contact, disease progression or death from any cause without verified relapse. Time-to-event distributions were estimated using the Kaplan-Meier method and compared with the log-rank test. Univariate Cox regression analysis was performed to examine the prognostic significance of the examined volumetric or MGMT related parameters. In the multivariate Cox analysis a backward selection procedure with removal criterion $p > 0.10$, identified a subclass of significant variables among the following: Sex (male vs. female), age ($<$ 50 vs \geq 50), performance status (0 vs 1 or 2), type of excision (partial/biopsy vs subtotal vs total), pre-radiochemotherapy net enhancing tumor, preoperative necrosis, preoperative T2 abnormality, and preoperative enhancing tumor. For the categorisation of the type of excision we used data from the surgeons based on their impression during surgery and in some cases on post-operative CT scans. It was categorised as total, subtotal or partial/biopsy if there was resection of \geq 99%, 75-99% and $<$ 75% of tumor volume, respectively. For all tests, $\alpha = 0.05$ level of significance was used. Analysis was conducted using SPSS 15.

Results

Between July 2005 and August 2007, sixty-five patients (37 males, 28 females), with a median age of 59 years were assigned in our study. Patient's characteristics at the time of enrollment, along with tumor location, performance status and tumor volumetric parameters are

shown in Table 1. All patients had surgical tissue diagnosis; 59 had undergone craniotomy and open biopsy followed by maximal feasible tumor resection (13 total resections, 33 subtotal resections and 13 partial resections or biopsies) and 6 received stereotactic biopsies.

Treatment delivery and toxicity

Treatment characteristics are shown in Table 2. One patient prematurely discontinued both radiotherapy and temozolomide due to severe hematologic toxic effects of concomitant treatment and eight other patients did not receive adjuvant temozolomide (2 due to death, 2 due to progressive disease, 3 due to non-fatal toxic effects and one due to patient refusal), although they had completed concurrent treatment. Hematologic complications were

Table 1 Selected patient and tumor characteristics

N = 65	
Age (years)	Median (range)
Median	59 (22-74)
N (%)	
< 50	15 (23)
\geq 50	50 (77)
Sex	
Male	37 (57)
Female	28 (43)
PS	
0	34 (52)
1	25 (38)
2	6 (9)
Surgery	
Partial/Biopsy*	19 (29)
Subtotal resection	33 (51)
Total resection	13 (20)
Hemisphere	
Left	33 (51)
Right	29 (45)
Bilateral	3 (5)
Location	
Temporal	20 (31)
Parietal	20 (31)
Occipital	3 (5)
Frontal	17 (26)
Deep	8 (12)
Volumetric parameters	Median (range)
Enhancing tumor (cm ³)	34.7 (2.3-117.5)
Preoperative T2 abnormality (cm ³)	108.1 (3.8-230.9)
Necrosis (cm ³)	5.8 (0-57)
PreRCT Net-enhancing tumor (cm ³)	11 (0-80.8)

* 6 cases of stereotactic biopsy are included

Table 2 Treatment

Radiotherapy (RT)	
Median total dose (range)	60 (48-60)
Median number of fractions (range)	30 (24-33)
Chemotherapy (CT)	
· CT concomitant with RT	65 (100)
Total number of cycles delivered	417
Median number of cycles delivered (range)	7 (2-8)
· Adjuvant CT (post RT)	56 (86)
Total number of cycles delivered	343
Median number of cycles delivered (range)	6 (1-12)
Treatment status	N (%)
Completed	31(48)
Discontinuation	34(52)
PD	19(29)
Death	5(8)
Toxicity (non fatal)	5(8)
Refused to continue	4(6)
Clinical deterioration	1(2)

by far the most common. Overall, twenty-three patients (35%) suffered from grade 3 or 4 hematologic toxicity. More specifically, thrombocytopenia presented in 16 (25%), leucopenia in 13 (20%), neutropenia in 14 (22%) and anemia in 1 (2%) of the patients. Regarding moderate to severe non-hematologic complications, 3 patients presented with thromboembolic events and 3 other patients suffered from pulmonary infections, one of whom died as a consequence of pneumocystis carinii pneumonia.

Response and survival

Thirty-one patients (48%) responded to therapy; seven of them completely (11%, 95% Confidence interval [CI]:


4.4-20.9) and twenty-four partially (37%, 95% CI: 25.3-49.8). Twenty-seven patients had stable disease (42%, 95% CI: 29.4-54.4) and five developed progressive disease. Two patients were not evaluated for response due to early tumor death and patient refusal.

After a median follow-up of 49.4 months, 61 patients experienced disease progression, 58 died and 2 patients were lost to follow-up. The median overall survival was 16.3 months (range 3.5-45.4 and 95% CI: 13.4-19.2) and the first and second year survival rate was 74% and 32%, respectively. The median progression-free survival was 9.5 months (range 2.8-35.8 and 95% CI: 6.8-12.1) and the first and second year progression-free survival rate was 38% and 11%, respectively. The corresponding Kaplan-Meier curves are depicted on Figure 3.

Correlations of survival with clinical and volumetric parameters

In the univariate Cox regression analysis, sex, age and extent of surgery were not found to be statistically significant predictors for OS or PFS, whereas PS was found to influence both OS and PFS (Hazard ratio[HR] = 2.27, 95% CI:1.33-3.86; Wald's *p* = 0.003 and HR = 2.45, 95% CI:1.46-4.13; Wald's *p* = 0.001, respectively).

Concerning the volumetric measurements (using continuous values), preoperative T2 abnormality was not found to be a significant factor for survival or PFS, while for the other parameters, we identified a 2% excess risk of mortality for each one-unit increase in pre-radiochemotherapy net-enhancing tumor volume (HR = 1.02, 95% CI:1.01-1.04; Wald's *p* = 0.001) and a 2% excess risk of progression for each one-unit increase in preoperative necrosis volume (HR = 1.02, 95% CI: 1.00-1.05; Wald's *p* = 0.021). Moreover, a 1% excess risk of mortality and progression was observed for each one-unit increase in preoperative enhancing tumor volume



(HR = 1.01, 95% CI: 1.00-1.02; Wald's $p = 0.037$ and HR = 1.01, 95% CI: 1.00-1.02; Wald's $p = 0.041$, respectively) (Table 3).

Furthermore, in the exploratory analysis a prognostic threshold was detected for the preRCT net-enhancing tumor volume regarding both OS and PFS (75th percentile = 22,2 cm³). Patients with large remaining tumor postoperatively (preRCT net-enhancing tumor volume ≥ 22.2 cm³) had a reduced OS versus those with small remaining tumor (log-rank $p = 0.002$). The HR for large tumors was 2.59 (95% CI: 1.38-4.87, Wald's $p = 0.003$). In terms of PFS, large remaining tumors were associated with shorter PFS (log-rank $p = 0.002$) and the HR was 2.64 (95% CI: 1.38-5.02, Wald's $p = 0.003$) (Table 4 and 5 and Figure 4). For the rest of the volumes measured no significant association was found in terms of OS or PFS.

Multivariate Cox regression analysis revealed that only performance status and preRCT net-enhancing tumor volume remained significant independent predictors of OS, while performance status and preoperative necrosis independently predicted PFS (Table 6). More specifically, preRCT net-enhancing tumor volume was associated with an increased risk for death (HR = 1.02, 95% CI: 1.00-1.04, Wald's $p = 0.023$). As expected, performance status of 1-2 was also associated with increased risk for death (HR = 2.01, 95% CI: 1.15-3.51, Wald's $p = 0.014$). Regarding PFS, preoperative necrosis and performance status were associated with increased risk for disease progression (HR = 1.02, 95% CI: 1.00-1.04, Wald's

$p = 0.030$ and HR = 2.88, 95% CI: 1.66-5.01, Wald's $p < 0.001$ respectively).

MGMT assessments in association with volumetric parameters and with patient outcome

Evaluation of *MGMT* mRNA expression was possible in 41/44 (93.2%), of *MGMT* protein expression in 35/44 (79.5%), and of *MGMT* promoter methylation status in 23/44 (52.3%) of the glioblastoma cases with available tissue blocks. RQ values for *MGMT* mRNA ranged from undetectable to 0.484 (mean: 0.028, \pm SD: 0.075, median: 0.011). Ten out of 23 evaluable tumors (43.5%) were found methylated for at least one target with MS-MLPA (relative peak values > 0.25) and 13 tumors were unmethylated (relative peak values ≤ 0.25); only 3/10 methylated tumors (approximately 13% of all evaluable cases) were positive for all targets included in the assay with relative peak values > 0.75 , i.e. the threshold set for the evaluation of complete methylation at the corresponding sites [27]. *MGMT* IHC results are shown in Table 7.

Although *MGMT* methylated tumors showed lower mRNA expression, there was no statistically significant association between the results of the three methods. Neither *MGMT* promoter methylation nor *MGMT* expression (mRNA/protein) showed statistically significant association with patient PFS and OS.

In association with volumetric parameters, tumors with a higher rate of *MGMT* protein expression ($> 20\%$,

Table 3 Univariate Cox regression analysis of clinical factor and volume measurement with OS and PFS

	Overall Survival			Progression-free Survival		
	HR	95% CI	p	HR	95% CI	p
Sex						
Female	1			1		
Male	1.18	0.69-2.02	0.538	1.32	0.79-2.23	0.289
Age						
< 50	1			1		
≥ 50	1.54	0.83-2.89	0.174	1.43	0.77-2.67	0.259
PS						
0	1			1		
1 or 2	2.27	1.33-3.86	0.003	2.45	1.46-4.13	0.001
Surgery						
Partial/Biopsy	1			1		
Subtotal	2.02	0.95-4.32	0.069	0.96	0.53-1.73	0.881
Total	1.33	0.68-2.60	0.409	0.70	0.33-1.48	0.352
Volumetry						
PreOp Enhancing tumor	1.01	1.00-1.02	0.037	1.01	1.00-1.02	0.041
PreOp T ₂ abnormality	1.00	1.00-1.01	0.276	1.00	1.00-1.01	0.387
PreOp Necrosis	1.02	1.00-1.04	0.067	1.02	1.00-1.05	0.021
PreRCT Net-enhancing tumor	1.02	1.01-1.04	0.001	1.01	1.00-1.02	0.068

Table 4 Median OS and PFS according to pre-radiochemotherapy net enhancing tumor volume

	Events	Median	95% CI	Log-rank p
Overall Survival				0.002
Small (< 75th percentile = 22.2 cm ³)	44/49	20.10	15.24-24.96	
Large (> = 75th percentile = 22.2 cm ³)	14/16	11.28	6.96-15.60	
Progression-free Survival				0.002
Small (< 75th percentile = 22.2 cm ³)	46/49	11.70	7.70-15.71	
Large (> = 75th percentile = 22.2 cm ³)	15/16	7.84	4.37-11.31	

Log-rank test for overall and progression-free survival in association with large and small pre-radiochemotherapy net enhancing tumor volume

n = 6) were less necrotic at diagnosis than tumors with a lower rate of or negative for MGMT protein with IHC (n = 11) (Mann-Whitney *p* = 0.021). MGMT parameters were not associated with the rest of pre- or post-operative tumor volumetry parameters.

Discussion

In the present study we explored the prognostic significance of several volumetric parameters for the progression-free and the overall survival in glioblastoma patients. All patients were treated with the same radiochemotherapy scheme, in order to ensure the uniformity of the population. Concerning the efficacy and toxicity of the radiochemotherapy scheme our results are in accordance with current literature [22,28].

As in most other studies dealing with glioblastoma patients [29-32], we confirmed the importance of the performance status as a factor influencing both survival parameters. It is of note, however, that the extent of resection was not found to be statistically significant. This may be explained by the subjectivity of this particular assessment (surgeons' impression and qualitative rough estimation of postoperative CT images) and dictates the need for the application of volumetry with early (within 48 h) postoperative MRIs. We can further assume, in this context, that the extent of resection may not be significant, when it is expressed as a percentage of the initial volume, but it is probably the absolute volume of the tumor remnant, which is the determinant factor affecting the prognosis.

The volumetric parameters, which were assessed in this study, were the pre-radiochemotherapy net-enhancing tumor volume and the preoperative enhancing tumor, necrosis and T2-abnormality. We found that

pre-radiochemotherapy net-enhancing tumor volume and preoperative volume of necrosis are significant predictors of outcome. Our results are consistent with prior reports on the significance of volumetric parameters of glioblastomas.

In a recent study reported by Saraswathy et al. [33] the investigators evaluated the prognostic importance of MR markers (anatomic, perfusion, diffusion and metabolic) in pre-treatment (radiochemotherapy) scans in patients with GBMs. They found that all of the above parameters were associated with survival. In particular, the volume of contrast enhancing lesion was inversely correlated with survival.


In another study by Keles et al. [34] the authors concluded that the volume of residual disease (VRD) at the beginning of chemotherapy was a significant predictor for both survival time and time to progression in patients with recurrent glioblastomas. These patients, however, were neither chemotherapy-naive, nor newly diagnosed. In a different volumetric study of the same group [35] evaluating the effect of extent of tumor resection and VRD on survival, the authors reported that both of these parameters influenced significantly TTP and OS in patients with glioblastoma. This patient group is not uniform, though, as they did not all receive chemotherapy and the protocols are not noted. In addition, the volumetric measurements were not only performed in MR scans but CT images, so the results are not really comparable.

On the contrary, in the multivariate analysis of Tralins et al., investigated the use of 18 F-FDG PET for the guidance of radiation dose escalation in GBM patients, it was found that only the volume of uptake and not the volumes measured on MR images, including the T1-

Table 5 Univariate Cox analysis of pre-radiochemotherapy net enhancing tumor volume with OS and PFS

	Overall Survival			Progression-free Survival		
	HR	95% CI	p	HR	95% CI	p
PreRCT Net-enhancing tumor						
Small (< 75th percentile = 22.2 cm ³)	1	-		1	-	
Large (> 75th percentile = 22.2 cm ³)	2.59	1.38-4.87	0.003	2.64	1.38-5.02	0.003

Univariate Cox analysis for association of large and small pre-radiochemotherapy net enhancing tumor volume with overall survival and progression free survival



weighted gadolinium enhancement, were of prognostic significance for survival or time to progression [36]. That disagreement with our results could be explained by the different time of MRI acquisition, since in the above study it was performed during the course of radiotherapy.

In a recent study of Cao et al. [37] the authors concluded that only the vascular leakage volume measured 1-2 weeks prior radiation therapy in dynamic contrast enhanced T2*-weighted images is of predictive value for survival and not the volume of contrast enhanced lesion measured in T1 weighted (nondynamic) images. However, in this study only patients with residual tumor volume > 4 cm³ were included and not all of the

patients received chemotherapy and that could explain the discrepancy with our results.

At this point, we have to note that the prognostic value of contrast enhancement has certain limitations. This has been illustrated in a recent study by Piroth et al. [38], correlating the volumetric findings of MRI with those of positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl)-L-tyrosine (FET) and concluding that the latter has a stronger prognostic impact. To summarize, although our study shows that pre-RCT net-enhancing tumor has a prognostic value, the results from the literature are rather contradictory in this context.

Concerning the influence of preoperative enhancing tumor volume, although it was found, in univariate

Table 6 Multivariate Cox Analysis

	Overall Survival			Progression-free Survival		
	HR	95% CI	p	HR	95% CI	Wald-p
Age						
< 50	1	-				
≥ 50	1.74	0.91-3.30	0.092			
PS						
0	1	-		1		
1 or 2	2.01	1.15-3.51	0.014	2.88	1.66-5.01	< 0.001
Sex						
Female				1		
Male				1.61	0.93-2.79	0.090
PreOp Necrosis						
				1.02	1.00-1.04	0.030
PreOp Enhancing tumor						
	1.01	1.00-1.02	0.066			
PreRCT Net-enhancing tumor						
	1.02	1.00-1.04	0.023			

Table 7 MGMT immunohistochemistry

	n	%
<i>Evaluable results</i>	35/44	79.5
MGMT absence (\leq 5% positive tumor cells)	18/35	51.4
MGMT presence ($>$ 5% positive tumor cells)	17/35	48.6
<i>Low MGMT expression (\leq 20% positive)</i>	11/17	64.7
<i>High MGMT expression ($>$ 20% positive)</i>	6/17	35.3

analysis, to exert a negative impact on OS and PFS, this effect disappeared when adjusted for other significant predictors in the multivariate analysis. Our results are almost identical with the results of Weber et al. [39] in a study evaluating the prognostic factors in cerebellar GBM. Similarly, in a large retrospective study from Lacroix et al. [29] the multivariate analysis of 416 patients with GBM did not show any correlation of preoperative tumor volume with survival. There are numerous other studies [40-42] supporting the lack of prognostic importance of the preoperative enhancing tumor volume. On the contrary, Xue et al. concluded [43] that the accurate preoperative measurement of tumor volume with computer-based three-dimensional reconstruction is an important prognostic factor in high-grade gliomas. The description of the regions of interest that were delineated is not mentioned (contrast enhancement, margins, edema etc.), and additionally, the population of the study is not uniform, comprising anaplastic astrocytomas and glioblastomas altogether.

The most logical explanation for the difference in prognostic significance between pre and postoperative enhancing volume is the variation of the extent of resection. Since extent of the resection is not primarily correlated with the volume of the tumor, but with other factors as well (e.g. location, infiltration of critical areas), there is no distinct correlation between those two volumes. We also have to take into consideration that a variable period of time usually intervenes between the operation and the initiation of treatment, during which tumor re-growth may occur, thus rendering the pre-treatment volume the most decisive factor for survival.

Necrosis is the imaging hallmark of GBM [44] and is believed to indicate rapid growth and malignant behavior [45]. We found that the volume of preoperative necrosis is a significant independent prognostic factor that negatively affects progression free survival, confirming several earlier studies pointing out this negative impact [29,42]. In this context, it was interesting to observe that tumors with a high rate of MGMT protein positive tumor cells were significantly less necrotic, a finding that may be related to the recently shown decreased tumorigenicity of MGMT expressing cells in preclinical models [46]. However, there are recent

volumetric studies that failed to show any correlation between the absolute volume of necrosis and survival [47-49]. Our finding suggests that large volume of necrosis is indicative of a more aggressive phenotype, which is also in accordance with the well established pathological view that large necroses are associated with sinister prognosis. Moreover, the necrotic core is associated with hypoxia, which has been shown to be a factor of poor response to radio or chemotherapy, possibly due to up-regulation of vascular endothelial growth factor (VEGF) expression that stimulates angiogenesis [50-54]. To our knowledge there is no volumetric study correlating the absolute volume of necrosis measured in preoperative MR scan in glioblastoma patients with PFS. Interestingly there was no correlation with overall survival. This could be partially explained by the different therapies following recurrence, as many of them contained anti-VEGF agents, which would be more beneficial for tumors with high VEGF levels [55].

The last preoperative volume measured was the T2 abnormality (high intensity signal in T2-weighted MR sequence). That volume includes the necrotic core, the enhancing tumor and a perimetric zone, consisting of vasogenic edema and tumor cells [56,57]. In our study there was no association between that volume and PFS or OS. This is in accordance with the results of Crawford et al. [47] and Li et al. [49]. That result seems straightforward since that volume includes a great amount of edema, which is correlated with the dose of the prescribed corticosteroids and, consequently, is not a reliable measure of tumor burden.

Our study, certainly, points out that the precise volume determination of anatomic parameters is still essential in brain tumor research. It is simple, accurate, cost-effective and easily applicable from most oncological specialties. There are also several other imaging modalities (perfusion and diffusion weighted MRI, proton MR spectroscopic imaging, PET-CT) which can play a more significant role, maybe more important than the volumetry of anatomic lesions [33,36,58-60]. More specifically, the use of amino acid tracers in PET has been shown in recent studies to be superior compared to MRI both in planning volumetric resection [61], as well as in predicting the outcome of glioblastoma patients prior and after RCT [38,62]. In addition, the significant correlation of the pretreatment volume of enhancement with overall survival, leads us to conclude that shortening (no longer than 6 weeks) of the interval between surgery and initiation of radiochemotherapy could be of great importance to survival, since it overcomes the problem of tumor regrowth [63]. This interval however, in the light of data presented by Blumenthal et al. [64], should not be earlier than 4 weeks allowing enough

time for recovery of the brain from the surgical injury and edema.

There are certainly some drawbacks that we need to mention. As it has been pointed out in our previous study [23], the lack of homogeneity in the MRI scans, as well as the process of digitization, may cause several variations in tumor delineation and the subsequently determined volumes. In addition, as the MRI was not performed during the optional time window of the first 48 h after surgery, visualization of the enhancing lesion was probably affected by postoperative changes. Moreover, our analysis was based on a small sample size, which may invoke the usual statistical uncertainties.

In this study, we did not observe any association of *MGMT* related parameters with patient outcome. It should be noticed, however, that the MLPA method used to determine *MGMT* promoter methylation yielded evaluable results in only half the samples available for this investigation; the method works on paraffin tissue extracts but it requires relatively preserved DNA, which we only could obtain in a limited number of cases, as evaluated by a multiplex control DNA PCR assay. In comparison to the usually applied MSP-PCR, MLPA has the advantage of providing information on the methylation status of multiple sites in the *MGMT* regulatory region in a semi-quantitative manner [27]. The degree of this epigenetic change seems to be of predictive value, since tumors with incomplete *MGMT* promoter methylation are reported to fail on temozolomide, while those with complete methylation show a significant trend to respond to this treatment [65]. The rate of tumors with complete methylation in our series was comparable to this report, but statistics could not be performed since the absolute number of cases was low. These results, as well as the lack of concordance among *MGMT* promoter methylation status, mRNA and protein expression results, once again reflect the problems encountered when assessing *MGMT* status on routine histologic material, as already reported in previous comparative studies [66].

Conclusions

Our study showed that the volume of residual net-enhancing tumor prior to radiochemotherapy significantly affects survival in glioblastoma patients, although relevant literature data are inconsistent. Additionally, the volume of preoperative necrosis seems to be of prognostic significance for the PFS. The other preoperative volumetric parameters studied (enhancing tumor, T2 high signal abnormality) did not significantly affect either OS or PFS. It is obvious that volumetry can still play a significant role in defining patients who run a greater risk if treated with conventional therapy (radiotherapy plus temozolomide). For these patients,

alternative treatments should be sought and better stratification for future studies could be achieved. A high expression rate of *MGMT* protein in glioblastomas may be related to a more indolent disease phenotype.

Acknowledgements

This work has been supported by a HeCOG research grant (TRANS_17/09) and by a research grant from General Secretariat for Research and Technology, Ministry of Development, Athens, Greece (PENED 3/583).

Author details

¹Department of Radiation Oncology, "Papageorgiou" Hospital, Thessaloniki, Greece. ²Department of Radiation Oncology, Interbalkan Medical Center, Thessaloniki, Greece. ³Department of Pathology, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece. ⁴Department of Neurosurgery, St Luke's Hospital, Thessaloniki, Greece. ⁵Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece. ⁶Department of Medical Oncology, "Papageorgiou" Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece. ⁷Department of Neurosurgery, "AHEPA" Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece. ⁸Department of Radiation Oncology, Interbalkan Medical Center, Asklipiou 10, 57001, Pylaia Thessaloniki, Greece.

Authors' contributions

GI was the primary investigator and wrote the manuscript and has contributed in the enrolment of patients and treatment, VK carried out the molecular genetic studies and contributed to the writing of the manuscript, AC has been involved in drafting the manuscript, DT evaluated IHC stains, AE performed the statistical analysis, SL has contributed to the acquisition of data and the therapeutic management, DM and PS has contributed to the initial design of the study, the enrolment of patients and treatment, GF has made substantial contributions to the conception and design of the study and to the enrolment of patients and the treatment. All the authors have given final approval of the version to be published.

Competing interests

The authors declare that they have no competing interests.

Received: 12 July 2011 Accepted: 3 January 2012

Published: 3 January 2012

References

1. Welsh J, Sanan A, Gabayan AJ, Green SB, Lustig R, Burri S, Kwong E, Stea B: **GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.** *Int J Radiat Oncol Biol Phys* 2007, **68**(1):159-65, Epub 2007 Feb 27.
2. Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G: **Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.** *Int J Radiat Oncol Biol Phys* 2009, **73**(2):473-8, Epub 2008 Jun 12.
3. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr: **Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol.** *Int J Radiat Oncol Biol Phys* 2004, **60**(3):853-60.
4. Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C, Souhami L, Chen A, Pham H, Mehta M: **A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.** *Int J Radiat Oncol Biol Phys* 2006, **65**(5):1422-8, Epub 2006 Jun 5.
5. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, Pintilie M, Bernstein M: **Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma.** *Int J Radiat Oncol Biol Phys* 1998, **41**(5):1005-11.

6. Nieder C, Andratschke N, Wiedenmann N, Busch R, Grosu AL, Molls M: **Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome.** *Strahlenther Onkol* 2004, **180**(7):401-7, Review.
7. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J, Meyer M: **Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme.** *Int J Radiat Oncol Biol Phys* 2009, **75**(1):164-9.
8. Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen S, Nelson DF, Mehta MP, Yung WK, Radiation Therapy Oncology Group: **Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710.** *Int J Radiat Oncol Biol Phys* 2006, **66**(3):818-24, Epub 2006 Aug 2.
9. Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanu E, Ghilezan N, Zamboglou N, Dimitriadis A, Sofroniadis I, Fountzilas G: **Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial.** *Int J Radiat Oncol Biol Phys* 2004, **59**(4):1018-26.
10. Kurek R, Kalogera-Fountzila A, Muskalla K, Dafni U, Schnabel T, Kober B, Roddiger S, Martin T, Fountzilas G, Zamboglou N: **Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer.** *Strahlenther Onkol* 2003, **179**(5):292-7.
11. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J, Wazer DE: **The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation.** *Int J Radiat Oncol Biol Phys* 1995, **32**(3):635-41.
12. Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M, Wannenmacher M: **Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy.** *Radiother Oncol* 1999, **53**(2):119-25.
13. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, Dimopoulos MA, Aravantinos G, Zamboglou N, Baltas D, Pavlidis N: **Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer.** *Anticancer Res* 2002, **22**(3):1903-8.
14. Burghardt E, Baltzer J, Tulusan AH, Haas J: **Results of surgical treatment of 1028 cervical cancers studied with volumetry.** *Cancer* 1992, **70**(3):648-55.
15. Kikuchi S, Sakuramoto S, Kobayashi N, Shimao H, Sakakibara Y, Sato K, Kakita A: **Tumor volumetry: proposal of a new concept to predict lymph node metastasis in early gastric cancer.** *Anticancer Res* 2000, **20**(5C):3669-74.
16. Stupp R, Roila F, ESMO Guidelines Working Group: **Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.** *Ann Oncol* 2009, **20**(Suppl 4):126-8, Review.
17. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JB: **Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.** *N Engl J Med* 2000, **343**(19):1350-4, Erratum in: *N Engl J Med* 2000 Dec 7;343(23):1740.
18. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group: **Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.** *Lancet Oncol* 2009, **10**(5):459-66, Epub 2009 Mar 9.
19. Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R: **Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.** *Lancet Oncol* 2008, **9**(1):29-38, Epub 2007 Dec 21.
20. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME: **MGMT promoter methylation in malignant gliomas: ready for personalized medicine.** *Nat Rev Neurol* 2010, **6**(1):39-51, Epub 2009 Dec 8. Review.
21. Brell M, Tortosa A, Verger E, Gil JM, Viñolas N, Villá S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T, Graus F: **Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas.** *Clin Cancer Res* 2005, **11**(14):5167-74.
22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group: **Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.** *N Engl J Med* 2005, **352**(10):987-96.
23. Iliadis G, Selvariadis P, Kalogera-Fountzila A, Fragkoulidi A, Baltas D, Tselis N, Chatziosiriou A, Misailidou D, Zamboglou N, Fountzilas G: **The importance of tumor volume in the prognosis of patients with glioblastoma: Comparison of computerized volumetry and geometrical models.** *Strahlenther Onkol* 2009, **185**(11):743-50, Epub 2009 Nov 10.
24. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG: **Response criteria for phase II studies of malignant glioma.** *J Clin Oncol* 1990, **8**:1277-80.
25. Livak KJ, Schmittgen TD: **Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.** *Methods* 2001, **25**(4):402-8.
26. Capper D, Mittelbronn M, Meyermann R, Schittenhelm J: **Pitfalls in the assessment of MGMT expression and its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.** *Acta Neuropathol* 2008, **115**(2):249-59, Epub 2007 Oct 27.
27. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P: **MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.** *Lab Invest* 2007, **87**(10):1055-65, Epub 2007 Aug 13.
28. Nieder C, Adam M, Grosu AL: **Combined modality treatment of glioblastoma multiforme: the role of temozolomide.** *Rev Recent Clin Trials* 2006, **1**(1):43-51, Review.
29. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: **A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.** *J Neurosurg* 2001, **95**(2):190-8.
30. Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS: **Chang S; Glioma Outcomes Investigators: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.** *J Neurosurg* 2003, **99**(3):467-73.
31. Hentschel SJ, Sawaya R: **Optimizing outcomes with maximal surgical resection of malignant gliomas.** *Cancer Control* 2003, **10**(2):109-14, Review.
32. Ammirati M, Vick N, Liao YL, Ciric I, Mikhael M: **Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas.** *Neurosurgery* 1987, **21**(2):201-6.
33. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ: **Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy.** *J Neurooncol* 2009, **91**(1):69-81, Epub 2008 Sep 23.
34. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS: **Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.** *J Neurosurg* 2004, **100**(1):41-6.
35. Keles GE, Anderson B, Berger MS: **The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.** *Surg Neurol* 1999, **52**(4):371-9.
36. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM: **Volumetric analysis of 18 F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.** *J Nucl Med* 2002, **43**(12):1667-73.
37. Cao Y, Nagesh V, Hamstra D, Tsien CI, Ross BD, Chenevert TL, Junck L, Lawrence TS: **The extent and severity of vascular leakage as evidence of tumor aggressiveness in high-grade gliomas.** *Cancer Res* 2006, **66**(17):8912-7.

38. Piroth MD, Holy R, Pinkawa M, Stoffels G, Kaiser HJ, Galldiks N, Herzog H, Coenen HH, Eble MJ, Langen KJ: **Prognostic impact of postoperative, pre-irradiation (18F)-fluoroethyl-L-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.** *Radiother Oncol* 2011, **99**(2):218-24, Epub 2011 Apr 16.
39. Weber DC, Miller RC, Villà S, Hanssens P, Baumert BG, Castadot P, Varlet P, Abacioglu U, Igdem S, Szutowicz E, Nishioka H, Hofer S, Rutz HP, Ozsahin M, Taghian A, Mirimanoff RO: **Outcome and prognostic factors in cerebellar glioblastoma multiforme in adults: a retrospective study from the Rare Cancer Network.** *Int J Radiat Oncol Biol Phys* 2006, **66**(1):179-86, Epub 2006 Jul 11.
40. Wang YY, Yang GK, Li SY, Baol XF, Wu CY: **Prognostic factors for deep situated malignant gliomas treated with linac radiosurgery.** *Chin Med Sci J* 2004, **19**(2):105-10.
41. Kowalczuk A, Macdonald RL, Amidei C, Dohrmann G, Erickson RK, Hekmatpanah J, Krauss S, Krishnasamy S, Masters G, Mullan SF, Mundt AJ, Sweeney P, Vokes EE, Weir BK, Wollman RL: **Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas.** *Neurosurgery* 1997, **41**(5):1028-36, discussion 1036-8.
42. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE: **Prognostic significance of preoperative MRI scans in glioblastoma multiforme.** *J Neurooncol* 1996, **27**(1):65-73.
43. Xue D, Albright RE Jr: **Preoperative anaplastic glioma tumor volume effects on patient survival.** *J Surg Oncol* 1999, **72**(4):199-205.
44. Burger PC, Heinz ER, Shibata T, Kleihues P: **Topographic anatomy and CT correlations in the untreated glioblastoma multiforme.** *J Neurosurg* 1988, **68**(5):698-704.
45. Segall HD, Destian S, Nelson MD Jr, et al: **CT and MR imaging in malignant gliomas.** In *Malignant Cerebral Glioma*. Edited by: Apuzzo MLJ. Park Ridge, IL: American Association of Neurological Surgeons; 1990:63-77.
46. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, Aghi M, Jacques A, Murray D, Sabri S, Abdulkarim B: **MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.** *Neuro Oncol* 2010, **12**(8):822-33, Epub 2010 Feb 23.
47. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ: **Relationship of preoperative metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.** *J Neurooncol* 2009, **91**(3):337-51, Epub 2008 Nov 15.
48. Flynn JR, Wang L, Gillespie DL, Stoddard GJ, Reid JK, Owens J, Ellsworth GB, Salzman KL, Kinney AY, Jensen RL: **Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme.** *Cancer* 2008, **113**(5):1032-42.
49. Li X, Jin H, Lu Y, Oh J, Chang S, Nelson SJ: **Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.** *NMR Biomed* 2004, **17**(1):10-20.
50. Raza SM, Lang FF, Aggarwal BB, Fuller GN, Wildrick DM, Sawaya R: **Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis.** *Neurosurgery* 2002, **51**(1):2-12, discussion 12-3. Review.
51. D' Angelo MG, Afanasieva T, Aguzzi A: **Angiogenesis in transgenic models of multistep carcinogenesis.** *J Neurooncol* 2000, **50**(1-2):89-98. Review.
52. Shweiki D, Itin A, Soffer D, Keshet E: **Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.** *Nature* 1992, **359**:843-845.
53. Plate KH, Breier G, Weich HA, Risau W: **Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.** *Nature* 1992, **359**:845-848.
54. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG: **Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.** *Neuro Oncol* 2005, **7**:134-153.
55. Chamberlain MC: **Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.** *Cancer* 2010, **116**(17):3988.
56. Earnest F, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS, Axley PL: **Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy.** *Radiology* 1988, **166**(3):823-7.
57. Kelly PJ, Daumas-Duport C, Scheithauer BW, Kall BA, Kispert DB: **Stereotactic histologic correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms.** *Mayo Clin Proc* 1987, **62**(6):450-9.
58. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ: **Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.** *J Magn Reson Imaging* 2004, **19**(5):546-54.
59. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ: **3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI.** *Int J Radiat Oncol Biol Phys* 2004, **59**(1):126-37.
60. Thiele F, Ehmer J, Piroth MD, Eble MJ, Coenen HH, Kaiser HJ, Schaefer WM, Buell U, Boy C: **The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma.** *Phys Med Biol* 2009, **54**(18):5525-39, Epub 2009 Aug.
61. Piroth BJ, Levivier M, Goldman S, Massager N, Wikler D, Dewitte O, Bruneau M, Rorive S, David P, Brotschi J: **Positron emission tomography-guided volumetric resection of supratentorial high-grade gliomas: a survival analysis in 66 consecutive patients.** *Neurosurgery* 2009, **64**(3):471-81, discussion 481.
62. Piroth MD, Pinkawa M, Holy R, Klotz J, Nussen S, Stoffels G, Coenen HH, Kaiser HJ, Langen KJ, Eble MJ: **Prognostic value of early [18 F] fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.** *Int J Radiat Oncol Biol Phys* 2011, **80**(1):176-84, Epub 2010 Jun 18.
63. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ: **Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.** *Neuro Oncol* 2009, **11**(6):842-52, Epub.
64. Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, Rogers CL, Corn BW: **Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database.** *J Clin Oncol* 2009, **27**(5):733-9, Epub 2008 Dec 29.
65. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M: **A microarray-based DNA methylation study of glioblastoma multiforme.** *Epigenetics* 2009, **4**(4):255-64, Epub 2009 May 29.
66. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W, Goepfert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel MC: **Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.** *Clin Cancer Res* 2009, **15**(21):6683-93, Epub 2009 Oct 27.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2407/12/3/prepub>

doi:10.1186/1471-2407-12-3

Cite this article as: Iliadis et al.: Volumetric and MGMT parameters in glioblastoma patients: Survival analysis. *BMC Cancer* 2012 **12**:3.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

